INFINITY PHARMACEUTICALS, INC.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $2.6M | $1.9M | $1.7M | $3.0M | $22.1M | $6.0M |
| Operating income | −$44.8M | −$45.1M | −$38.5M | −$45.7M | −$11.9M | −$36.4M |
| Net income | −$44.4M | −$45.3M | −$40.5M | −$47.1M | −$11.3M | −$41.8M |
| Total assets | $42.2M | $84.8M | $39.3M | $49.0M | $60.2M | $59.4M |
| Total liabilities | $61.2M | $63.2M | $62.3M | $41.3M | $7.8M | $11.6M |
| Equity | −$19.1M | $21.6M | −$23.0M | $7.7M | $52.5M | $47.7M |
| EPS (diluted) | $-0.50 | $-0.53 | $-0.68 | — | — | — |
| Shares out. | 89.2M | 88.6M | 57.4M | 56.9M | 52.0M | 50.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −1729.4%
- Net margin
- −1711.1%
- Return on equity
- 232.9%
- Return on assets
- −105.3%
- Return on capital (ROCE)
- −157.2%
- Liabilities / assets
- 145.2%
- Debt / equity
- —
- Book value / share
- $-0.21
- Revenue growth (YoY)
- 39.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -69.53distress
- Accruals / assets
- −4.6%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Bankruptcy or receivership · Director / officer changeSep 29, 2023
- Delisting / listing-standard noticeSep 13, 2023
- Delisting / listing-standard noticeSep 11, 2023
- Costs from exit or disposal · Director / officer change · Other material eventSep 1, 2023
- Costs from exit or disposal · Director / officer change · Other material eventJul 25, 2023
- Terminated a material agreement · Other material eventJul 24, 2023
- Shareholder voteJul 14, 2023
- Other material eventJul 3, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.